Can a common painkiller stop brain tumors? new study hopes to find out
NCT ID NCT02429570
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests meclofenamate, a drug once used for pain, in 30 patients with brain metastases that have come back or grown despite prior treatments. The goal is to see if the drug can prevent new brain metastases and whether a larger trial is feasible. Researchers will monitor MRI scans and side effects to decide next steps.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Meclofenamate (a pain drug repurposed to prevent new brain metastases)
- What this could lead to
- If it works, this could point toward a new way to slow or prevent brain metastases from growing, offering more time for patients.
- What could go wrong
- This is a very early pilot study with only 30 people. It is designed mainly to see if a larger trial is possible, not to prove effectiveness. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Apr 2015
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-80 * KPS ≥ 60 * At least one recurrent or progressive brain metastasis (es) from any solid primary tumor that is visible on MRI as assessed by the patient's treating physician. * Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable. * There is no limit on the number of brain metastases. * Surgical resection or SRS to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated. * Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist. Exclusion Criteria: * Inability to get brain MRI +/- contrast * Progressive systemic disease * Known leptomeningeal metastases * Primary Brain tumor * Active Intracranial Hemorrhage * Surgery less than two weeks before enrollment * GI hemorrhage (active or in recent 6 months) * Concurrent anti-platelet therapy * Concurrent anti-coagulation therapy * Active bleeding diathesis * Platelet count ≤ 70,000/mm3 * International normalized ratio (INR) \> 1.6 and a Partial Thromboplastin Time (PTT) \> 40 seconds * Serum Creatinine \>2 mg/dL OR CrCL \<30ml/min * AST or ALT \> 200 U/L * Hemoglobin \<8 g/dL * Allergy to meclofenamate or other NSAID * Inability to tolerate PO dosing * Steroid dose increased in the most recent two weeks. * Pregnancy * Cardiac Arrhythmia requiring medical management and/or pacemaker. * Known congestive heart failure requiring medical management
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Progressive brain metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baptist Health South Florida
Miami, Florida, 33143, United States
-
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center at Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.